ClinicalTrials.gg
RecruitingNCT07448142Updated Oct 15, 2026

Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer

A Phase 2 interventional study of Low-dose radiotherapy and Pucotenlimab in Colorectal Cancer (CRC), sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 15, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies testing xelox in Colorectal Neoplasms — 12 open to participants now, 12 under way, none of them phase 3. xelox · Colorectal Neoplasms.

Planned enrollment
13th of 19
50 · median 54
Started
2026
with 3 others
Phase 2
13 of 19
10 open now
Primary completion
2027-09
later than 8 of 11 live
Registered
17th of 19
by date

Among the 19 studies testing xelox in Colorectal Neoplasms, this one is the 13th largest by planned enrollment, is one of 4 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 8 of the 11 other live ones, and was the 17th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

12 of the 19 studies testing xelox in Colorectal Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About xelox

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing xelox in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, open-label, randomized, parallel-group phase II trial evaluating the efficacy and safety of a low-dose radiotherapy sensitization strategy combined with a PD-1 antibody (pucotenlimab) and CAPEOX as neoadjuvant therapy in patients with pMMR/MSS locally advanced rectal adenocarcinoma. Participants will be randomized 1:1 to receive either 2 Gy or 5 Gy low-dose radiotherapy. Low-dose radiotherapy is delivered as a single fraction of 2 Gy (Arm A) or 5 Gy (Arm B). On the day after radiotherapy, participants will start pucotenlimab 200 mg IV Q3W (administered on Day 2 of each 21-day cycle) plus CAPEOX chemotherapy. Tumor response will be assessed after two cycles using endoscopy and pelvic magnetic resonance imaging (MRI). Participants with non-progressive disease, defined as partial response (PR) or stable disease (SD), will receive no further low-dose radiotherapy and will continue pucotenlimab plus CAPEOX for cycles 3 and 4. Participants with local progressive disease, defined as enlargement of the rectal tumor, will receive salvage chemoradiotherapy according to the center's standard operating procedures. Participants who develop distant metastases will receive further treatment determined by a multidisciplinary team (MDT). After four cycles, participants who achieve a clinical complete response (cCR) may enter a watch-and-wait strategy. Participants without cCR and without progressive disease will undergo radical surgery according to total mesorectal excision (TME) principles. Participants with progressive disease will receive individualized treatment determined by the MDT.

Read the detailed description

Rectal cancer remains a major global health burden, with a higher risk of local recurrence and worse prognosis compared with colon cancer. The introduction of total mesorectal excision (TME) has substantially reduced local recurrence rates, and the incorporation of peri-operative radiotherapy and chemotherapy has further improved oncologic outcomes. Current National Comprehensive Cancer Network (NCCN) guidelines recommend pre-operative chemoradiotherapy followed by radical surgery for patients with stage II-III locally advanced rectal cancer.In recent years, total neoadjuvant therapy (TNT) has emerged as an optimized treatment paradigm, increasing pathologic complete response (pCR) rates to approximately 20-40%, and even higher when combined with immunotherapy. For patients achieving a clinical complete response (cCR) after neoadjuvant therapy, a non-operative "watch-and-wait" strategy has been shown to be safe and effective, allowing organ preservation without compromising long-term oncologic outcomes.However, most patients with proficient mismatch repair (pMMR) or microsatellite-stable (MSS) rectal cancer derive limited benefit from immune checkpoint blockade alone. Preclinical and clinical evidence suggests that radiotherapy, particularly low-dose radiotherapy (LDRT), may enhance antitumor immune responses by modulating the tumor microenvironment and promoting immune sensitization. Whether different low-dose radiotherapy regimens can differentially enhance the efficacy of immunotherapy combined with chemotherapy in pMMR/MSS locally advanced rectal cancer remains unknown.To address this question, the present study is designed as a prospective, open-label, randomized, parallel-group phase II clinical trial evaluating a low-dose radiotherapy sensitization strategy combined with a PD-1 antibody (pucotenlimab) and CAPEOX chemotherapy as neoadjuvant treatment.Eligible participants with pMMR/MSS locally advanced rectal adenocarcinoma will be randomized in a 1:1 ratio to receive either 2 Gy or 5 Gy low-dose radiotherapy. On the day following radiotherapy, all participants will initiate systemic treatment with pucotenlimab 200 mg administered intravenously every 3 weeks (Q3W) on Day 2, in combination with CAPEOX chemotherapy in 21-day cycles. An early response assessment will be performed after two cycles of neoadjuvant treatment using endoscopy and pelvic MRI. Participants with PR or SD will discontinue any further low-dose radiotherapy and will complete the remaining two cycles of pucotenlimab plus CAPEOX. Participants with local progressive disease, defined as enlargement of the rectal lesion, will receive salvage chemoradiotherapy, with the treatment regimen and implementation procedures following the center's standardized SOP. Participants with distant metastases will undergo MDT review to determine subsequent treatment based on disease status, treatment response, and tolerability. A further response assessment will be performed after four cycles. Participants achieving cCR may enter watch-and-wait surveillance. Participants who do not achieve cCR and have no progressive disease will undergo standard TME surgery. Participants with progressive disease will undergo MDT review for individualized management. The primary objective of this study is to compare the complete response rate, defined as the sum of clinical complete response and pathological complete response, between the two low-dose radiotherapy regimens. Secondary objectives include long-term disease control, survival outcomes, surgical quality metrics, postoperative morbidity, stoma rates, and patient-reported quality of life. This study aims to determine whether optimization of low-dose radiotherapy can enhance immune-chemotherapy efficacy and increase organ preservation opportunities in patients with pMMR/MSS locally advanced rectal cancer.

03

Conditions studied

  • Colorectal Cancer (CRC)

Keywords

  • Colorectal cancer
  • Neoadjuvant therapy
  • Low-dose radiotherapy
  • Immunotherapy
  • Pucotenlimab
  • CAPEOX
  • Total neoadjuvant therapy
  • Organ preservation
  • Complete Response Rate
  • Disease-free survival
  • Overall survival
04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written provided prior to any study-specific procedures.
  • Age 18 to 75 years at the time of enrollment.
  • confirmed rectal adenocarcinoma.
  • Tumor located within 10 cm from the anal verge, as assessed by endoscopy or imaging.
  • Locally advanced disease, defined as clinical stage T2N+ or T3-T4a (any N) based on pelvic magnetic resonance imaging (MRI).
  • Proficient mismatch repair (pMMR) or microsatellite-stable (MSS) tumor status confirmed by immunohistochemistry or molecular testing.
  • No evidence of distant on preoperative imaging, including chest, abdominal, and pelvic computed tomography (CT).
  • (ECOG) performance status 0-1.
  • Adequate organ function as defined by:
  • ≥1.5 × 10⁹/L
  • count ≥100 × 10⁹/L
  • ≥90 g/L
  • Total ≤1.5 × (ULN)
  • (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN
  • ≥50 mL/min
  • Thyroid-stimulating hormone (TSH) within normal limits
  • Women of must have a negative pregnancy test and agree to use effective during the study and for a protocol-defined period after the last dose.
  • Men with partners of childbearing potential must agree to use effective contraception during the study and for a protocol-defined period after the last dose.

Exclusion criteria

Exclusion Criteria

  • Clinical T4b disease, defined as tumor invasion into adjacent organs or structures on baseline imaging.
  • Evidence of distant outside the pelvis.
  • Prior pelvic or abdominal radiotherapy.
  • Prior treatment with or other systemic anticancer therapy for rectal cancer.
  • Active or history of disease requiring systemic treatment, except for conditions considered low risk for recurrence (e.g., vitiligo, resolved childhood asthma).
  • Ongoing use of systemic therapy, including equivalent to >10 mg/day of prednisone, within 2 weeks prior to enrollment.
  • Known (HIV) infection.
  • Active virus infection with positive hepatitis B surface antigen and high viral load, or virus infection requiring treatment.
  • Uncontrolled active infection or other serious medical condition that, in the investigator's judgment, would compromise patient safety or study compliance.
  • History of another within 5 years, except for adequately treated basal cell carcinoma of the skin, cervical carcinoma in situ, or other malignancies with negligible risk of recurrence.
  • Known or allergy to pucotenlimab, oxaliplatin, capecitabine, or any of their .
  • Pregnant or breastfeeding women.
  • Any condition that, in the investigator's opinion, makes the participant unsuitable for study participation.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    2 Gy LDRT + Pucotenlimab + CAPEOX

    Neoadjuvant low-dose radiotherapy (2 Gy) followed by pucotenlimab 200 mg IV Q3W plus CAPEOX chemotherapy. Participants receive one 2 Gy fraction of low-dose radiotherapy in each of cycles 1 and 2, for a planned total dose of 4 Gy before any salvage treatment, combined with pucotenlimab and CAPEOX in a response-adapted neoadjuvant treatment strategy. Response is assessed after two cycles. Participants with PR or SD complete cycles 3 and 4 with pucotenlimab plus CAPEOX without further low-dose radiotherapy; those with local progression receive salvage chemoradiotherapy according to the center's SOP; and those with distant metastases receive MDT-directed treatment. After four cycles, cCR permits watch-and-wait surveillance, non-cCR without progression leads to standard TME surgery, and progressive disease is managed through MDT review.

    Radiation: Low-dose radiotherapy · Drug: Pucotenlimab · Drug: CAPEOX/XELOX

  • Experimental
    5 Gy LDRT + Pucotenlimab + CAPEOX

    Neoadjuvant low-dose radiotherapy (5 Gy) followed by pucotenlimab 200 mg IV Q3W plus CAPEOX chemotherapy. Participants receive one 5 Gy fraction of low-dose radiotherapy in each of cycles 1 and 2, for a planned total dose of 10 Gy before any salvage treatment, combined with pucotenlimab and CAPEOX in a response-adapted neoadjuvant treatment strategy. Response is assessed after two cycles. Participants with PR or SD complete cycles 3 and 4 with pucotenlimab plus CAPEOX without further low-dose radiotherapy; those with local progression receive salvage chemoradiotherapy according to the center's SOP; and those with distant metastases receive MDT-directed treatment. After four cycles, cCR permits watch-and-wait surveillance, non-cCR without progression leads to standard TME surgery, and progressive disease is managed through MDT review.

    Radiation: Low-dose radiotherapy · Drug: Pucotenlimab · Drug: CAPEOX/XELOX

Interventions

  • RadiationLow-dose radiotherapy

    Low-dose radiotherapy is delivered to the primary rectal tumor and regional lymphatic drainage areas using IMRT or 3D-CRT. Participants receive one fraction at the start of each of the first two 21-day cycles: 2 Gy per fraction in Arm A (planned total dose 4 Gy) or 5 Gy per fraction in Arm B (planned total dose 10 Gy), excluding any salvage radiotherapy. No further low-dose radiotherapy is administered during cycles 3 and 4 in participants with PR or SD at the two-cycle assessment. Local progressive disease is managed with salvage chemoradiotherapy according to the center's SOP.

  • Pucotenlimab is a programmed cell death protein 1 (PD-1) monoclonal antibody. It is administered at a fixed dose of 200 mg by intravenous infusion on Day 2 of each 21-day cycle, every 3 weeks (Q3W), during the neoadjuvant treatment phase.

  • DrugCAPEOX/XELOX

    Drug page: XeloxStudies of XeloxXelox pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    CAPEOX chemotherapy consists of oxaliplatin 130 mg/m² administered intravenously on Day 1 and capecitabine 1000-1250 mg/m² administered orally twice daily on Days 1-14 of each 21-day cycle during neoadjuvant therapy.

06

What researchers measure

Primary outcomes

  1. Complete Response Rate (CR)

    The Combined CR rate is defined as the percentage of participants achieving either Clinical Complete Response (cCR) or Pathologic Complete Response (pCR). cCR is assessed via pelvic MRI, digital rectal examination (DRE), and endoscopy following the completion of 4 cycles of neoadjuvant therapy (each cycle is 21 days). For patients who do not achieve cCR and subsequently undergo radical surgery (scheduled 2-4 weeks after the last dose of neoadjuvant therapy), pCR is assessed by pathological examination of the resected surgical specimen (Tumor Regression Grading, TRG 0) according to the AJCC/College of American Pathologists (CAP) guidelines. For participants receiving salvage chemoradiotherapy, response assessment and surgery will follow the salvage treatment schedule specified in the protocol and the center's SOP.

    Time frame: From the start of neoadjuvant therapy until the completion of pre-operative assessment (approximately 12 weeks) and the time of surgery (approximately 14-16 weeks).

Secondary outcomes

  1. 3-year Disease-Free Survival (DFS)

    Disease-free survival is defined as the time from randomization to the first documented occurrence of tumor recurrence (local or distant) or death from any cause, whichever occurs first.

    Time frame: Up to 3 years after randomization.

  2. 5-year Overall Survival (OS)

    Overall survival is defined as the time from randomization to death from any cause.

    Time frame: Up to 5 years after randomization.

  3. Distant Metastasis Rate

    The proportion of participants who develop distant metastasis during follow-up, confirmed by radiologic or pathologic assessment.

    Time frame: Up to 5 years after randomization.

  4. R0 Resection Rate

    The proportion of participants who achieve microscopically margin-negative (R0) resection at the time of surgery.

    Time frame: At the time of surgery.

  5. Postoperative Surgical Complication Rate

    The proportion of participants experiencing postoperative surgical complications, graded according to standard surgical complication criteria.

    Time frame: Within 30 days after surgery.

  6. Protective Stoma Rate

    The proportion of participants who undergo prophylactic diverting stoma creation at the time of surgery.

    Time frame: At the time of surgery.

  7. Quality of Life (EORTC QLQ-C30)

    Quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), version 3.0.

    Time frame: From baseline through follow-up (up to 5 years).

07

Study locations

1 of 1 sites recruiting
  • Dept. of Colorectal Surgery, Sun Yat-sen University Cancer Center. Yuexiu District, Dongfeng East Road 651
    Guangzhou, Guanggong 510060, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2027, 17 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 17 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Mar 4, 2026
StartActual
Mar 15, 2026
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2032
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion removed; 1 exclusion criterion removed
What changed in the criteria
Inclusion criteria
  • RemovedCircumferential resection margin (CRM) ≥2 mm and no involvement of the mesorectal fascia on baseline MRI.
Exclusion criteria
  • RemovedCircumferential resection margin (CRM) <2 mm or definite involvement of the mesorectal fascia on baseline MRI.
Oct 15, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionComplete Response Rate (CR): how it is measured was reworded
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Eligibility 1 inclusion criterion removed; 1 exclusion criterion removed
    What changed in the criteria
    Inclusion criteria
    • RemovedCircumferential resection margin (CRM) ≥2 mm and no involvement of the mesorectal fascia on baseline MRI.
    Exclusion criteria
    • RemovedCircumferential resection margin (CRM) <2 mm or definite involvement of the mesorectal fascia on baseline MRI.
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionComplete Response Rate (CR): how it is measured was reworded
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07448142
Responsible party
Pei-Rong Ding (Director of the Department of Colorectal Surgery, Sun Yat-sen University) — Principal investigator
First posted
Mar 4, 2026
Start date
Mar 15, 2026
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2032 (estimated)
Last update
Oct 15, 2026

Study contacts

Wu Jiang
Contact
jiangwu@sysucc.org.cn
+86-15989120166
Pei-Rong Ding
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pucotenlimab · Xelox

Start the discussion